The results of this study are consistent with earlier research reporting that lidocaine, a volatile phenolic amide, has an antiproliferative effect on SW480 and HCT116 colon cancer cell lines by inhibiting epidermal growth factor receptor (EGFR) through induction of microRNA-520a-3p, which directly targets EGFR [51]. This evidence concerns the gene EGFR and malignant colon neoplasm.